Frazier Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Frazier Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,123,107	Closed	-$55M	–	47
2021 Q3	$55M	Hold	3,123,107	–	–	4.4%	7
2021 Q2	$30.3M	Hold	3,123,107	–	–	2.79%	10
2021 Q1	$33.4M	Buy	3,123,107 +70,000	+2%	+$866K	2.68%	10
2020 Q4	$44.9M	Buy	3,053,107 +264,664	+9%	+$3.82M	3.46%	9
2020 Q3	$39.6M	Buy	2,788,443 +33,443	+1%	+$333K	3.55%	7
2020 Q2	$22.3M	Buy	2,755,000 +311,191	+13%	+$1.93M	1.96%	12
2020 Q1	$9.55M	Buy	+2,443,809	New	+$9.24M	1.08%	13

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Frazier Management's TRIL Position: Q4 2021 in Review

Frazier Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 3,123,107 shares — an estimated $55M sold.

Frazier Management first reported a position in TRIL in Q1 2020 and held it in 7 quarters. The position peaked at $55M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Frazier Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Frazier Management sold 3,123,107 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $55M.
Frazier Management first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 7 quarters.
Frazier Management's Trillium Therapeutics Inc. position peaked at $55M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Frazier Management's 13F filing for Q4 2021, filed 8 Feb 2022.